1. Introduction {#sec1-ijms-20-02452}
===============

The maintenance of body temperature (T~b~) in mammalians is critical for survival and internal homeostasis. The main brain structure involved in controlling T~b~ is the hypothalamus, which receives inputs from the thermoreceptors located in both the brain and the periphery. Depending on these inputs, homeostatic changes are subsequently induced, causing sweating or shivering \[[@B1-ijms-20-02452]\]. In particular, the preoptic area (POA) and dorsomedial hypothalamus (DMH) are critical hypothalamic areas for thermoregulation. In these areas, based on the firing rate responses to changes in local brain temperature, electrophysiological recordings have shown three different neuronal populations: warm-sensitive neurons (\~30%), cold-sensitive neurons (\~6%), and insensitive neurons (\~60%), \[[@B2-ijms-20-02452],[@B3-ijms-20-02452]\]. Activation of the thermally-responsive GABAergic and glutamatergic neurons in the ventral part of the lateral preoptic nucleus (vLPO) and the dorsal part of the dorsomedial hypothalamus (DMD), respectively, decreases temperature, physical activity, and metabolic rate. On the contrary, GABAergic neurons in the DMD promote the increase of T~b~, energy expenditure, and physical activity \[[@B4-ijms-20-02452]\].

Recently, it has also been found that T~b~ can be internally regulated in a circadian manner by endogenous signals from other parts of the hypothalamus \[[@B4-ijms-20-02452],[@B5-ijms-20-02452]\], specifically in the suprachiasmatic nucleus (SCN) \[[@B1-ijms-20-02452],[@B6-ijms-20-02452],[@B7-ijms-20-02452]\]. The SCN regulates the circadian rhythmicity of several physiological responses \[[@B1-ijms-20-02452]\], including the oscillatory decrease of the thermoregulatory threshold of heat production during day time and heat loss during night time in diurnal species \[[@B1-ijms-20-02452],[@B8-ijms-20-02452],[@B9-ijms-20-02452]\]. However, the mechanisms underlying this circadian modulation of T~b~ remain unclear. Interestingly, the hypothalamus, including the SCN, DMH, and POA, are rich in melatonin (MLT) MT~1~ and MT~2~ receptors \[[@B7-ijms-20-02452],[@B10-ijms-20-02452],[@B11-ijms-20-02452],[@B12-ijms-20-02452],[@B13-ijms-20-02452]\], and the activation of these MLT receptors modulates numerous physiological effects including the control of T~b~ \[[@B14-ijms-20-02452]\].

MLT is produced in the pineal gland, mostly during the dark phase in both diurnal and nocturnal species \[[@B12-ijms-20-02452],[@B15-ijms-20-02452]\]. The circadian production and release of MLT are controlled by the SCN \[[@B16-ijms-20-02452]\]. Most of the physiological effects of MLT result from the activation of two high-affinity G-protein coupled receptors (GPCRs), MT~1~ (pK~i~ = 10.09) and MT~2~ (pK~i~ = 9.42), both of which are widely expressed in the mammalian brain \[[@B7-ijms-20-02452],[@B10-ijms-20-02452],[@B17-ijms-20-02452]\]. The specific localization of the two MLT receptor subtypes in different regions of the brain and/or neuronal populations \[[@B11-ijms-20-02452],[@B18-ijms-20-02452],[@B19-ijms-20-02452],[@B20-ijms-20-02452]\] partially explains the selective and differential functional activity of the two MLT receptor subtypes, such as in sleep \[[@B18-ijms-20-02452],[@B21-ijms-20-02452],[@B22-ijms-20-02452],[@B23-ijms-20-02452]\], anxiety \[[@B24-ijms-20-02452]\], pain \[[@B25-ijms-20-02452],[@B26-ijms-20-02452]\], circadian rhythms \[[@B27-ijms-20-02452]\], and depression \[[@B28-ijms-20-02452]\]. In addition to these high-affinity MLT receptors, another low-affinity MLT binding site, termed MT~3~ (pKi = 6.0), has been reported \[[@B29-ijms-20-02452],[@B30-ijms-20-02452]\]. Given its both hydrophilic and lipophilic nature, MLT can easily pass through the cell membrane and bind nuclear receptors, including retinoic acid receptor-related orphan receptors (RORs) \[[@B31-ijms-20-02452]\].

It is known that MLT decreases T~b~ during the night in diurnal species \[[@B1-ijms-20-02452]\]. Clinical studies have shown that exogenous administration of MLT suppresses the physiological increase in T~b~ observed during daytime \[[@B32-ijms-20-02452],[@B33-ijms-20-02452]\] and has hypothermic properties at the dose of 5 mg/kg \[[@B34-ijms-20-02452],[@B35-ijms-20-02452],[@B36-ijms-20-02452],[@B37-ijms-20-02452],[@B38-ijms-20-02452]\]. Similar results have been demonstrated in preclinical studies in diurnal animals in which administration of MLT acted as a hypothermic agent in the active/light phase in fat sand rats and Marshall broiler chickens \[[@B39-ijms-20-02452],[@B40-ijms-20-02452]\]. However, the neurobiological mechanism through which MLT exerts this hypothermic effect, as well as the selective contribution of the three MLT receptor subtypes, are yet to be investigated.

Therefore, we investigated modifications in T~b~ produced by selectively activating the three MLT receptor subtypes across the light--dark cycle in rats. To achieve this aim, we tested the effects of the selective MT~2~ receptor partial agonist N-{2-\[(3-bromophenyl)-(4-fluorophenyl)amino\] ethyl}acetamide (UCM924) (pK~iMT1~ = 6.76; pK~iMT2~ = 9.27) \[[@B41-ijms-20-02452]\], the selective MT~1~ receptor partial agonist N-(2-{Methyl-\[3-(4-phenylbutoxy)phenyl\]amino}ethyl) acetamide (UCM871) (pK~iMT1~ = 8.93; pK~iMT2~ = 7.04) \[[@B42-ijms-20-02452]\], and the MT~3~ receptor agonist 5-Methoxycarbonylamino-N-acetyltryptamine (GR135531) (pK~iMT3~ = 29.5) on T~b~. The effects of UCM924, UCM871, and GR135531 were compared to those of MLT. In addition, selective and non-selective MLT receptor antagonists were also tested together with MLT and the other MLT receptor agonists/partial agonists to further dissect the MLT receptor subtypes involved in their thermoregulatory effects.

2. Results {#sec2-ijms-20-02452}
==========

In physiological conditions, as already known \[[@B1-ijms-20-02452],[@B9-ijms-20-02452]\], there are changes in T~b~ between the light and the dark phase; in particular, T~b~ oscillations mostly occur during the phase shift ([Figure 1](#ijms-20-02452-f001){ref-type="fig"}). During the shift from the dark to the light phase, the T~b~ drops from an average of 38.45 to 37.5 °C after the light turns on ([Figure 1](#ijms-20-02452-f001){ref-type="fig"}A). The opposite occurs during the shift from the light to the dark phase when the light is turned off ([Figure 1](#ijms-20-02452-f001){ref-type="fig"}B).

2.1. Effects of MLT Injected at the End of the Dark and of the Light Phases on T~b~ {#sec2dot1-ijms-20-02452}
-----------------------------------------------------------------------------------

As indicated in [Figure 2](#ijms-20-02452-f002){ref-type="fig"}A, the injection of MLT (40 mg/kg) at the end of the dark phase (5:00 a.m.) did not affect T~b~ during the end of the dark phase, the dark--light transition or the beginning of the light phase (two-way repeated measures ANOVA; interaction: F~17,323~ = 0.85, *p* = 0.635; treatment: F~1,323~ = 0.867, *p* = 0.363; time of the day: F~17,323~ = 31.835, *p* \< 0.001).

In contrast, when MLT (40 mg/kg) was injected at the end of the light phase (5:00 p.m.), it induced a significant decrease (*p* \< 0.05) in T~b~ from 5:45 p.m. to 6:45 p.m. that was close to the transition from the light to the dark phase ([Figure 2](#ijms-20-02452-f002){ref-type="fig"}B; interaction: F~17,408~ = 1.908, *p* = 0.016; treatment: F~1,408~ = 1.996, *p* = 0.171; time of the day: F~17,408~ = 10.658, *p* \< 0.001). Importantly, we observed no further effects of MLT on T~b~ after the light--dark transition or during the beginning of the dark phase. The selective MT~2~ receptor antagonist 4P-PDOT at a dose not affecting T~b~ ([Figure 2](#ijms-20-02452-f002){ref-type="fig"}D; interaction: F~17,340~ = 0.62, *p* = 0.876; treatment: F~1,340~ = 2.07, *p* = 0.166; time of the day: F~17,340~ = 4.86, *p* \< 0.001) blocked the effects of MLT ([Figure 2](#ijms-20-02452-f002){ref-type="fig"}C; interaction: F~17,391~ = 1.448, *p* = 0.111; treatment: F~1,391~ = 0.22, *p* = 0.643; time of the day: F~17,391~ = 11.486, *p* \< 0.001). Similarly, the pre-treatment with the selective MT~1~/MT~2~ receptor antagonist luzindole at the dose not affecting T~b~ ([Figure 2](#ijms-20-02452-f002){ref-type="fig"}F; interaction: F~17,408~ = 1.144, *p* = 0.309; treatment: F~1,408~ = 0.012, *p* = 0.912; time of the day: F~17,408~ = 9.289, *p* \< 0.001) also blocked the effects of MLT ([Figure 2](#ijms-20-02452-f002){ref-type="fig"}E; interaction: F~17,289~ = 0.989, *p* = 0.47; treatment: F~1,289~ = 0.11, *p* = 0.745; time of the day: F~17,289~ = 3.745, *p* \< 0.001).

2.2. Effects of the Selective MT~2~ Partial Agonist UCM924 Injected at the End of the Dark and of the Light Phases on T~b~ {#sec2dot2-ijms-20-02452}
--------------------------------------------------------------------------------------------------------------------------

As indicated in [Figure 3](#ijms-20-02452-f003){ref-type="fig"}A, the injection of UCM924 (40 mg/kg) at the end of the dark phase (5:00 a.m.) induced a significant decrease (*p* \< 0.05) in T~b~ immediately before the dark--light transition (from 6:45 a.m. to 7:30 a.m.), and did not affect T~b~ during the dark--light transition and at the beginning of the light phase (two-way repeated measures ANOVA; interaction: F~17,289~ = 0.2.406, *p* = 0.002; treatment: F~1,289~ = 2.286, *p* = 0.149; time of the day: F~17,289~ = 30.597, *p* \< 0.001).

In contrast, when UCM924 (40 mg/kg) was injected during the light phase (5:00 p.m.), it did not affect T~b~ during the end of the light phase, the dark--light transition or the beginning of the dark phase ([Figure 3](#ijms-20-02452-f003){ref-type="fig"}B; two-way repeated measures ANOVA; interaction: F~17,425~ = 0.785, *p* = 0.711; treatment: F~1,425~ = 0.311, *p* = 0.582; time of the day: F~17,425~ = 9.618, *p* \< 0.001).

The effects of UCM924 on T~b~ when injected during the dark phase were mediated by MT~2~ receptors since the pre-treatment with the selective MT~2~ receptor antagonist 4P-PDOT at a dose not affecting T~b~ ([Figure 3](#ijms-20-02452-f003){ref-type="fig"}D; interaction: F~17,272~ = 0.875, *p* = 0.605; treatment: F~1,272~ = 1.223, *p* = 0.285; time of the day: F~17,272~ = 22.848, *p* \< 0.001) blocked the effects of UCM924 ([Figure 3](#ijms-20-02452-f003){ref-type="fig"}C; interaction: F~17,272~ = 1.922, *p* = 0.016; treatment: F~1,272~ = 0.0.35, *p* = 0.821; time of the day: F~17,272~ = 30.468, *p* \< 0.001).

2.3. Effects of the Selective MT~1~ Partial Agonist UCM871 Injected at the End of the Dark and of the Light Phases on T~b~ {#sec2dot3-ijms-20-02452}
--------------------------------------------------------------------------------------------------------------------------

As indicated in [Figure 4](#ijms-20-02452-f004){ref-type="fig"}A, the injection of UCM871 (14 mg/kg) at the end of the dark phase (5:00 a.m.) did not affect T~b~ during the end of dark phase, the dark--light transition or the beginning of light phase (two-way repeated measures ANOVA; interaction: F~17,340~ = 0.842, *p* = 0.644; treatment: F~1,340~ = 0.538, *p* = 0.472; time of the day: F~17,340~ = 44.622, *p* \< 0.001).

In contrast, when UCM871 (14 mg/kg) was injected during the light phase (5:00 p.m.), it induced a significant increase (*p* \< 0.05) in T~b~ from 8:15 p.m. to 8:45 p.m. (dark phase) ([Figure 4](#ijms-20-02452-f004){ref-type="fig"}B; interaction: F~17,340~ = 1.634, *p* = 0.05; treatment: F~1,340~ = 2.045, *p* = 0.168; time of the day: F~17,340~ = 10.42, *p* \< 0.001). The effects of UCM871 on T~b~ when injected during the light phase were blocked by the pre-treatment with the MT~1~/MT~2~ receptor antagonist luzindole ([Figure 4](#ijms-20-02452-f004){ref-type="fig"}C; interaction: F~17,340~ = 0.67, *p* = 0.83; treatment: F~1,340~ = 1.22, *p* = 0.28; time of the day: F~17,340~ = 4.88, *p* \< 0.001) at a dose not affecting T~b~ (see [Figure 2](#ijms-20-02452-f002){ref-type="fig"}F; interaction: F~17,408~ = 1.144, *p* = 0.309; treatment: F~1,408~ = 0.012, *p* = 0.912; time of the day: F~17,408~ = 9.289, *p* \< 0.001).

2.4. Effects of the Selective MT~3~ Agonist GR135531 and Prazosin Injected at the End of the Light Phase on T~b~ {#sec2dot4-ijms-20-02452}
----------------------------------------------------------------------------------------------------------------

As indicated in [Figure 5](#ijms-20-02452-f005){ref-type="fig"}A, the injection of GR135531 (10 mg/kg) at the end of the light phase (5:00 p.m.) did not affect T~b~ during the end of the light phase, the dark--light transition or the beginning of dark phase (two-way repeated measures ANOVA; interaction: F~17,306~ = 0.94, *p* = 0.527; treatment: F~1,306~ = 0.342, *p* = 0.566; time of the day: F~17,306~ = 7.817, *p* \< 0.001). The effects of MLT on T~b,~ when injected during the light phase, were not mediated by MT~3~ receptors, since the pre-treatment with the non-selective α~1~/MT~3~ antagonist prazosin at a dose not affecting T~b~ ([Figure 5](#ijms-20-02452-f005){ref-type="fig"}C, interaction: F~17,357~ = 1.01, *p* = 0.446; treatment: F~1,357~ = 0.022, *p* = 0.882; time of the day: F~17,357~ = 7.588, *p* \< 0.001) did not block the effects of MLT ([Figure 5](#ijms-20-02452-f005){ref-type="fig"}B; interaction: F~17,340~ = 1.65, *p* = 0.050; treatment: F~1,340~ = 3.064, *p* = 0.095; time of the day: F~17,340~ = 10.086, *p* \< 0.001). Interestingly, the treatment with prazosin plus MLT induced a further decrease of T~b~ even during the dark phase at 8:00 p.m. ([Figure 5](#ijms-20-02452-f005){ref-type="fig"}B) that was not observed with MLT ([Figure 2](#ijms-20-02452-f002){ref-type="fig"}B) or prazosin ([Figure 5](#ijms-20-02452-f005){ref-type="fig"}C) alone.

3. Discussion {#sec3-ijms-20-02452}
=============

In this study, we investigated the effects of MLT and its three receptors on T~b~ during the light and the dark phase for the first time. To achieve this aim, we used a pharmacological approach employing MLT, the selective MT~1~ receptor partial agonist UCM871, the selective MT~2~ receptor partial agonist UCM924, the MT~3~ receptor agonist GR135531, and selective/non-selective MLT receptor antagonists, including the MT~2~ selective antagonist 4P-PDOT, the MT~1~/MT~2~ non-selective antagonist luzindole, and the MT~3~/α~1~ antagonist prazosin. The exogenous administration of MLT during the light phase decreased T~b~ immediately after the administration and before the light--dark phase shift, an effect blocked by both 4P-PDOT and luzindole. Interestingly, unlike MLT, neither UCM924 nor UCM871 produced a change in T~b~ during the light phase. In contrast, the selective MT~2~ partial agonist UCM924 administered at the end of the dark phase decreased T~b~ during the dark phase, just prior to the dark--light switch, whereas the selective MT~1~ partial agonist UCM871 injected at the end of the light phase increased T~b~ during the following dark phase. On the other hand, MT~3~ receptors did not seem to be involved in the regulation of T~b~, since the MT~3~ receptor agonist GR135531 and the MT~3~/α~1~ antagonist prazosin alone had not produced any effect on T~b~.

The rat circadian body temperature displays a cosine wave \[[@B39-ijms-20-02452]\], showing a temperature that oscillates around the 35.6--36 °C during the light phase and around 37.8--38 °C during the dark phase \[[@B43-ijms-20-02452]\]. The daily change in T~b~ shows a characteristic deviation at two different times, consistent with the switch between day (light phase) and night (dark phase) hours \[[@B44-ijms-20-02452]\]. The present study replicates the same physiological T~b~ deviation that was previously reported in nocturnal rodents \[[@B43-ijms-20-02452],[@B44-ijms-20-02452]\], with a daily T~b~ peak during the night, which is concomitant with the increase in the activity of the animals \[[@B45-ijms-20-02452]\].

In nocturnal rodents, T~b~ peaks during night time when MLT levels are high, and decreases during the light phase when MLT levels are low. In contrast, in diurnal species, T~b~ regulation follows the reverse direction in relation to MLT levels, showing a T~b~ peak during the light phase \[[@B45-ijms-20-02452]\] when circulating levels of MLT are very low (\~10 pg/mL) \[[@B12-ijms-20-02452],[@B15-ijms-20-02452],[@B46-ijms-20-02452]\]. However, the mechanism by which MLT regulates T~b~ has not been established.

The neuronal circuit controlling the regulation of T~b~ involves several structures including the SCN, SON, mPOA, and DMH \[[@B4-ijms-20-02452],[@B5-ijms-20-02452]\]. Notably, the hypothalamus is an area rich in MLT receptors \[[@B11-ijms-20-02452]\], and their expression may vary according to the phase and the time of the day \[[@B47-ijms-20-02452],[@B48-ijms-20-02452],[@B49-ijms-20-02452],[@B50-ijms-20-02452],[@B51-ijms-20-02452]\].

Previous reports have shown that exogenous MLT administration during the light phase induced a decrease in T~b~ in both humans and rodents \[[@B32-ijms-20-02452],[@B35-ijms-20-02452],[@B36-ijms-20-02452],[@B37-ijms-20-02452],[@B39-ijms-20-02452],[@B52-ijms-20-02452]\], although the active doses in humans are lower than those in rodents due to a significantly faster metabolism and very short half-life of MLT in the latter \[[@B53-ijms-20-02452]\]. Our findings confirm that exogenous MLT influences T~b~, and its effects are strictly dependent on the time of day: MLT reduces T~b~ only towards the end of the light phase and if administered during the light phase. In regard to its possible mechanism of action during the light phase, we found that both the selective MT~2~ antagonist 4P-PDOT and the non-selective MT~1~/MT~2~ antagonist luzindole blocked the T~b~ reduction due to MLT, yet neither the selective MT~1~ partial agonist UCM871 nor the selective MT~2~ partial agonist UCM924 recapitulated the effects of MLT on T~b~. These findings suggest that during the light phase, MLT needs to simultaneously activate both MT~1~ and MT~2~ receptors to modulate T~b~. Indeed, the selective activation/inhibition of only MT~1~ or MT~2~ receptors did not affect T~b~ during the day. In contrast, UCM871 and UCM924 produced changes in T~b~ at different times of the dark phase and of opposite magnitude: UCM871 enhanced T~b~ just after the light--dark transition, whereas UCM924 decreased T~b~ just before the dark--light transition. Importantly, unlike UCM871 and UCM924, MLT did not induce any change in T~b~ during the dark phase. We previously observed a similar time-of-day-dependent effect of MLT on sleep \[[@B23-ijms-20-02452]\]. However, it is interesting that when α~1~ receptors/MT~3~ receptors were blocked by prazosin, MLT decreased T~b~ also during the dark phase. These complex findings observed during the dark phase are likely dependent on the fact that during the dark phase there is a significant increase in the endogenous levels of MLT, and thus the expression of the two MLT receptors \[[@B19-ijms-20-02452]\], as well as the involvement of other receptors implicated in thermoregulation, such as α~1~ adrenoceptors \[[@B54-ijms-20-02452]\], probably vary.

Interestingly, it is now well recognized that MLT receptors can form MT~1~/MT~2~ hetero-oligomers and also heteromers with other receptors, and from a functional point of view, their properties are different from those of the corresponding homomers \[[@B55-ijms-20-02452],[@B56-ijms-20-02452]\]. Since MLT receptors as well as other receptors including α~1~-adrenoceptors are highly expressed in brain regions/nuclei involved in thermoregulation, we cannot exclude that some of the effects of MLT on T~b~ described here were mediated by these oligomers/heteromers. Future studies are needed to investigate the possible circadian variability in the formation and role of oligomers and/or heteromers of MLT receptors in hypothalamic nuclei regulating T~b~. Similarly, the potential contribution of nuclear receptors, among which RORs that are also activated by MLT \[[@B31-ijms-20-02452]\], is worth investigating.

The phase-dependent response of T~b~ to exogenous MLT may depend not only on the changes in the density of MLT receptors across the light--dark cycle, but also on the relative distribution and function of MT~1~ and MT~2~ receptors that control unique physiological responses in the brain, for example in sleep \[[@B21-ijms-20-02452],[@B22-ijms-20-02452],[@B23-ijms-20-02452]\], anxiety \[[@B18-ijms-20-02452],[@B24-ijms-20-02452]\], pain \[[@B25-ijms-20-02452],[@B26-ijms-20-02452],[@B57-ijms-20-02452]\], and depression \[[@B28-ijms-20-02452],[@B58-ijms-20-02452],[@B59-ijms-20-02452]\], and in the periphery, for example at the cardiovascular level \[[@B60-ijms-20-02452],[@B61-ijms-20-02452]\].

In conclusion, we have investigated the role of MLT receptors in thermoregulation, and found that during the light phase T~b~ is affected only if both MT~1~ and MT~2~ receptors are simultaneously activated. Further, during the dark phase, a time-dependent effect was found in that the activation of MT~1~ and MT~2~ produces an increase and decrease of T~b~ respectively. No effects on T~b~ of the MLT MT~3~ receptor subtype were evidenced. However, MT~1~ and MT~2~ receptors control T~b~ in synergy with other receptors including α~1~ adrenoceptors. These data further support the recent findings showing that the MT~1~ and MT~2~ receptors modulate physio-pathological functions in different and sometimes opposing ways, and in a time-of-day dependent manner. In particular, MT~1~ or MT~2~ agonists may be further tested for hypothermia or hyperthermia, respectively.

4. Materials and Methods {#sec4-ijms-20-02452}
========================

4.1. Animals {#sec4dot1-ijms-20-02452}
------------

Male Wistar rats (200--250 g, Charles River) were used for behavioral tests. All animals were housed at constant room temperature (20 °C) and humidity under a 12/12-h light--dark cycle (lights on at 7:30 a.m. and off at 7:30 p.m.) with food and water ad libitum. All experimental procedures were performed between 5:00 a.m. and 9:30 a.m. and between 5:00 p.m. to 9:30 p.m. The experimental protocol was approved by the Animal Ethics Committee (AUP\#5253, McGill University, QC, Canada) and followed the ethical guidelines of the Canadian Institute of Health Research for animal care and scientific use.

4.2. Drugs and Pharmacological Treatments {#sec4dot2-ijms-20-02452}
-----------------------------------------

The N-(2-{Methyl-\[3-(4-phenylbutoxy)phenyl\]amino}ethyl)acetamide (UCM871, 14 mg/kg) \[[@B42-ijms-20-02452]\] and N-{2-\[(3-bromophenyl)-(4-fluorophenyl)amino\] ethyl}acetamide (UCM924, 40 mg/kg) \[[@B41-ijms-20-02452]\] were synthesized by the University of Urbino, Italy, and by BioQuadrant Inc. (Montreal, Canada), respectively. Melatonin (40 mg/kg), luzindole (10 mg/kg), and prazosin hydrochloride (1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine hydrochloride; 10 mg/kg) were purchased from Sigma (St. Louis, MO, USA), and 4P-PDOT (4-phenyl-2-propionamidotetralin; 10 mg/kg) and GR135531 (5-Methoxycarbonylamino-N-acetyltryptamine, 10 mg/kg) from Tocris Bioscience (Ellisville, MO, USA). All drugs were dissolved in a vehicle composed of 70% dimethyl sulfoxide (MP Biochemicals, Solon, OH, USA) and 30% saline. The doses of UCM924, MLT, 4P-PDOT, and luzindole \[[@B23-ijms-20-02452],[@B25-ijms-20-02452],[@B26-ijms-20-02452]\], as well as UCM871 \[[@B62-ijms-20-02452]\], were chosen based on our previous experiments examining the potential pharmacological activity of these compounds. The doses of GR135531 and prazosin were based on the literature \[[@B63-ijms-20-02452],[@B64-ijms-20-02452]\]. Drugs were injected subcutaneously (s.c.; 0.5 mL) 15 min before the beginning of the experiment: 5:00 a.m. for dark--light or 5:00 p.m. for light--dark testing. The selective MLT MT~2~ receptor antagonist 4P-PDOT, the non-selective MLT MT~1~/MT~2~ receptor antagonist luzindole, and the MT~3~/α~1~ antagonist prazosin (pKi = 21.7) \[[@B65-ijms-20-02452]\] were injected 15 min prior the agonist/partial agonist. [Figure 6](#ijms-20-02452-f006){ref-type="fig"} describes the experimental protocol.

4.3. Assessment of Body Temperature {#sec4dot3-ijms-20-02452}
-----------------------------------

Body (rectal) temperature (T~b~) in awake animals was measured by goosing the animal using a Traceable Snap-in Module with probe (Fisher Science Education, S90862). The probe was inserted to a depth of 2 cm for no more than 10 s, whereas the tested individual was kept in a cotton bag. Animals were handled every day for five days before the experiments with the aim of habituating the animal to the testing procedure and thus minimizing the associated stress.

4.4. Statistical Analysis {#sec4dot4-ijms-20-02452}
-------------------------

Data analysis was conducted using the SigmaPlot statistical software version 13 (Systat Software, Inc.). After controlling for the normal distribution of the data, a two-way ANOVA for repeated measures was used to analyze the data using treatments (between) and testing time (within) as factors. Post hoc analyses were performed using the Bonferroni test for multiple comparisons. The effect of vehicle was compared with that of the different agonists/partial agonists, the antagonists alone, or the agonist/partial agonist plus the antagonist. All data were expressed as mean ± SEM. *p* \< 0.05 was considered significant. All figures were made using MATLAB software.

Temperature values were normalized as follow: \[Temperature at time X -- Average of Temperature (4:00 a.m./p.m. to 5:00 a.m./p.m.)\]/\[Average of Temperature (4:00 a.m./p.m. to 5:00 a.m./p.m.)\]. "Time X" indicates any time after the injection.
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![Body temperature (T~b~) changes during the light--dark cycle in rats exposed to a 12/12-h light--dark cycle. (**A**) T~b~ decreases during the transition from the dark phase to the light phase. (**B**) T~b~ increases during the transition from the light phase to the dark phase. Lights on at 7:30 a.m. and off at 7:30 p.m. Data represent mean value ± SEM. Veh: s.c. injection of vehicle.](ijms-20-02452-g001){#ijms-20-02452-f001}

![Changes in T~b~ after MLT administration (40 mg/kg) during the light and the dark phase. (**A**) MLT does not produce changes in T~b~ when administrated at 5:00 a.m. (**B**) MLT administrated during the dark phase (5:00 p.m.) decreases the T~b~ immediately after the administration compared with vehicle treated rats. (**C**) 4P-PDOT (10 mg/kg) pre-treatment blocks the effect of MLT on T~b~ during the light phase. (**D**) 4P-PDOT (10 mg/kg) injected during the light phase does not affect T~b~. (**E**) Pre-treatment with luzindole (10 mg/kg) blocks the effect of MLT on T~b~ during the light phase. (**F**) luzindole (10 mg/kg) injected during the light phase does not affect T~b~. Data are expressed as mean ± SEM (graded shades). Lights on at 7:30 a.m. and off at 7:30 p.m. \* *p* \< 0.05 vs. vehicle; two-way ANOVA for repeated measures followed by Bonferroni *post hoc* test. Inj: s.c. injection of either vehicle, MLT, MLT + 4P-PDOT, 4P-PDOT, MLT + luzindole, or luzindole.](ijms-20-02452-g002){#ijms-20-02452-f002}

![Changes in T~b~ after UCM924 (40 mg/kg, s.c.) treatment during the light and the dark phase. (**A**) UCM924 (40 mg/kg) administered at 5:00 a.m. (light phase) decreases T~b~ prior the light--dark shift compared with vehicle. (**B**) UCM924 (40 mg/kg) administered at 5:00 p.m. does not produce any change in the T~b~ compared with vehicle. (**C**) 4P-PDOT pre-treatment blocks the effect of UCM924 on T~b~ during the dark phase. (**D**) 4P-PDOT (10 mg/kg) injected during the dark phase does not affect T~b~. Data are expressed as mean ± SEM (graded shades). Lights on at 7:30 a.m. and off at 7:30 p.m. \* *p* \< 0.05 versus vehicle; two-way ANOVA for repeated measures followed by Bonferroni *post hoc* test. Inj: s.c. injection of either vehicle, UCM924, UCM924 + 4P-PDOT, or 4P-PDOT.](ijms-20-02452-g003){#ijms-20-02452-f003}

![Changes in T~b~ after UCM871 (14 mg/kg, s.c.) treatment during the light and the dark phase. (**A**) UCM871 administered at 5:00 a.m. (dark phase) does not produce any change in the T~b~ compared with vehicle. (**B**) UCM871 administered at 5:00 p.m. (light phase) increases T~b~ after the light--dark transition compared with vehicle. (**C**) Luzindole pre-treatment blocks the effect of UCM871 on T~b~. Data are expressed as mean ± SEM (graded shades). Lights on at 7:30 a.m. and off at 7:30 p.m. \* *p* \< 0.05 versus vehicle; two-way ANOVA for repeated measures followed by Bonferroni *post hoc* test. Inj: s.c. injection of either vehicle, UCM871, or UCM871 + luzindole.](ijms-20-02452-g004){#ijms-20-02452-f004}

![(**A**) Changes in T~b~ after the administration of the MLT MT~3~ agonist GR135531 (10 mg/kg) during the dark phase. (**B**) Prazosin (10 mg/kg) pre-treatment does not block the effects of MLT on T~b~ during the light phase. (**C**) Prazosin (10 mg/kg) injected during the light phase does not affect T~b~. Data are expressed as mean ± SEM (graded shades). Lights off at 7:30 p.m. \* *p* \< 0.05 versus vehicle; two-way ANOVA for repeated measures followed by Bonferroni *post hoc* test. Inj: s.c. injection of either vehicle, GR135531, MLT + prazosin, or prazosin.](ijms-20-02452-g005){#ijms-20-02452-f005}

![Schematic representation of the experimental design. Body temperature (T~b~) has been recorded every 15 min. For light--dark phase experiments, light was off at 7:30 p.m., whereas for dark--light phase experiments, light was on at 7:30 a.m. s.c.: subcutaneous.](ijms-20-02452-g006){#ijms-20-02452-f006}
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